Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response

Experimental Hematology

Volumn 35, Issue 10, 2007, Pages 1527-1537

  Lagneaux, Laurence ^a   Gillet, Nicolas ^b   Stamatopoulos, Basile ^a   Delforge, Alain ^a   Dejeneffe, Marielle ^a   Massy, Martine ^a   Meuleman, Nathalie ^a   Kentos, Alain ^c   Martiat, Philippe ^a   Willems, Luc ^b   Bron, Dominique ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CASPASE 8; DEATH RECEPTOR; DNA FRAGMENT; FLICE INHIBITORY PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DISEASE COURSE; DNA DEGRADATION; DOWN REGULATION; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR NECROSIS;

AGED; AGED, 80 AND OVER; ANTICONVULSANTS; APOPTOSIS; B-LYMPHOCYTES; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASES; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PHOSPHATIDYLSERINES; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 34548703581     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.06.014     Document Type: Article

References (61)

1. Keating M.J., Chiorazzi N., Messmer B., et al. Biology and treatment of chronic lymphocytic leukaemia. Hematology, the American Society of Hematology Education Program Book (2003), The American Society of Hematology, Washington, DC p. 153-175
2. Chiorazzi N., Rai K.R., and Ferrarini M. Mechanisms of disease chronic lymphocytic leukaemia. N Engl J Med 352 (2005) 804-805
3. Oscier D.G., Thompsett A., Zhu D., and Stevenson F.K. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukaemia defined by chromosomal abnormalities. Blood 89 (1997) 4153-4160
4. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., and Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukaemia. Blood 94 (1999) 1848-1854
5. Damle R.N., Wasil T., Fais F., et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukaemia. Blood 94 (1999) 1840-1847
6. Orchard J.A., Ibboston R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 (2004) 105-111
7. Wiestner A., Rosenwald A., Barry T.S., et al. ZAP-70 expression identifies a chronic lymphocytic leukaemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101 (2003) 4944-4951
8. Calin G.A., Liu C.G., Sevignani C., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 101 (2004) 11755-11760
9. Nabhan C., Gartenhaus R.B., and Tallman M.S. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukaemia: dawn of a new era. Leuk Res 28 (2004) 244-250
10. Byrd J.C., Peterson B.L., Morrison V.A., et al. Randomized phase II study of concurrent versus sequential treatment with rituximab with fludarabine in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: superior complete response rates with concurrent therapy. Blood 101 (2003) 6-14
11. Pepper C., Hoy T., and Bentley D.P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro and clinical drug resistance. Br J Cancer 76 (1997) 935-938
12. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12 (1998) 599-606
13. Vigushin D.M., and Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 12 (2002) 1-13
14. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13 (2001) 477-483
15. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
16. Romanski A., Basic B., Bug G., et al. Use a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 89 (2004) 419-426
17. Kuefer R., Hofer M.D., Altug V., et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90 (2004) 535-541
18. Sandor V., Bakke S., Robey R.W., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8 (2002) 718-728
19. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nature 1 (2001) 194-202
20. Cinatl Jr. J., Cinatl J., Hernaiz P.D., et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anti-Cancer Drugs 8 (1997) 958-963
21. Olsen C.M., Meussen-Elholm E.T., Roste L.S., and Tauboll E. Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7. Mol Cell Endocrinol 213 (2004) 173-179
22. Tang R., Faussat A.M., Majdak P., et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukaemia cells expressing P-gp and MRP1. Leukemia 18 (2004) 1246-1251
23. Blabeta R.A., Michaelis M., Hernaiz Driever P., and Cinatl Jr. J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25 (2005) 383-397
24. Gottlicher M., Minucci S., Zhu P., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 (2001) 6969-6978
25. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276 (2001) 36734-36741
26. Gottlicher M. Valproic acid can old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83 (2004) S91-S92
27. Achachi A., Florins A., Gillet N., et al. Valproate activates bovine leukaemia virus gene expression, triggers apoptosis, and induces leukaemia/lymphoma regression in vivo. Proc Natl Acad Sci U S A 102 (2005) 10309-10314
28. Lagneaux L., Delforge A., Bron D., De Bruyn C., and Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91 (1998) 2387-2396
29. Binet J.L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1981) 198-206
30. Campbell M.J., Zelenetz A.D., Levy S., and Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 29 (1992) 193-203
31. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139 (1991) 271-279
32. Secchiero P., Tiribelli M., Barbarotto E., et al. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol 205 (2005) 246-252
33. Kim W.U., Yoo S.A., Min S.Y., et al. Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol 144 (2006) 503-511
34. Wierda W.G., and O'Brien S.M. Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol 33 (2006) 202-209
35. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukaemia. J Clin Oncol 23 (2005) 4079-4088
36. Liu T., Kuljaca S., Tee A., and Marshall G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32 (2006) 157-165
37. Aron J.L., Parthun M.R., Marcucci G., et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102 (2003) 652-658
38. Lucas D.M., Davis M.E., Parthun M.R., et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18 (2004) 1207-1214
39. O'Connor O.A., Heaney M.L., Schwartz L., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 (2006) 166-173
40. Kawagoe R., Kawagoe H., and Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 26 (2002) 495-502
41. Rezacova M., Vavrova J., Vokurkova D., and Zaskodova D. Effect of valproic acid and antiapoptotic cytokines on differentiation and apoptosis induction of human leukemia cells. Gen Physiol Biophys 25 (2006) 65-79
42. Genini D., Budihardjo I., and Plukett W. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1 mediated caspase pathway. J Biol Chem 275 (2000) 29-34
43. Byrd J.C., Kitada S., Flinn I.W., et al. The mechanism of tumor cell clearance by Rituximab in vivo in patients with B-cell chronic lymphocytic leukaemia: evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
44. Pahler J.C., Ruiz S., Niemer I., et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 9 (2003) 4570-4577
45. Rowinski E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23 (2005) 9394-9407
46. Romano C., De Fanis U., Sellitto A., et al. Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. Immunol Lett 97 (2005) 131-139
47. Kang J., Kisenge R.R., Toyoda H., et al. Chemical sensitization and regulation of TRAIL-induced apoptosis in a panel of B-lymphocytic leukaemia cell lines. Br J Haematol 123 (2003) 921-932
48. Cheng J., Hylander B.L., Baer M.R., Chen X., and Repasky E.A. Multiple mechanisms underlie resistance of leukaemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 5 (2006) 1844-1853
49. MacFarlane M., Harper N., Snowden R.T., Dyer M.J., Barnett G.A., and Pringle J.H. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21 (2002) 6809-6818
50. Guo F., Sigua C., Tao J., et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 64 (2004) 2580-2589
51. Inoue S., MacFarlane M., Harper N., Wheat L.M., Dyer M.J., and Cohen G.M. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11 (2004) S193-S206
52. Watanabe K., Okamoto K., and Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12 (2005) 10-18
53. Ziauddin M.F., Yeow W.S., Maxhimer J.B., et al. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 8 (2006) 445-457
54. Schuchmann M., Schulze-Bergkamen H., Fleischer B., et al. Histone deacetylase inhibition by valproic acid down-regulates cFLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15 (2006) 227-230
55. MacFarlane M., Inoue S., Kohlhaas S.L., et al. Chronic lymphocytic leukemic cells exhibit apoptotic signalling via TRAIL-R1. Cell Death Differ 12 (2005) 773-782
56. Inoue S., Mai A., Dyer M.J.S., and Cohen G.M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 66 (2006) 6785-6792
57. Garofalo M., Romano G., Quintavalle, et al. Selective inhibition of PED protein sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. Int J Cancer 120 (2007) 1215-1222
58. Szegezdi E., Cahill S., Meyer M., O'Dwyer M., and Samali A. TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br J Cancer 94 (2006) 398-406
59. Chen J., Ghazawi F.M., Bakkar W., and Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 5 (2006) 71-81
60. Kuendgen A., Schmid M., Schlenk R., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106 (2006) 112-119
61. Garcia-Manero G., Kantarijan H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2';-deoxycytidine with valproic acid in patients with leukaemia. Blood 108 (2006) 3271-3279